MDxHealth SA (NASDAQ:MDXH) Receives $7.75 Average Target Price from Brokerages

Shares of MDxHealth SA (NASDAQ:MDXH) have received a consensus rating of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $7.75.

MDXH has been the subject of a number of analyst reports. TD Cowen raised their price objective on MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday. Lake Street Capital lifted their price target on MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday. BTIG Research upped their price target on shares of MDxHealth from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday. Wall Street Zen upgraded shares of MDxHealth to a “hold” rating in a research note on Saturday, August 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MDxHealth in a report on Wednesday, October 8th.

MDxHealth Stock Down 8.3%

MDXH stock opened at $3.64 on Thursday. MDxHealth has a 1-year low of $1.35 and a 1-year high of $5.33. The stock has a market cap of $172.13 million, a price-to-earnings ratio of -4.14 and a beta of 1.68. The company has a current ratio of 1.31, a quick ratio of 1.22 and a debt-to-equity ratio of 13.81. The company’s 50 day moving average is $4.32 and its 200 day moving average is $3.06.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The business had revenue of $27.43 million during the quarter, compared to analysts’ expectations of $24.11 million. MDxHealth has set its FY 2025 guidance at EPS. Sell-side analysts predict that MDxHealth will post -1.15 EPS for the current fiscal year.

Institutional Trading of MDxHealth

Several institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP bought a new stake in shares of MDxHealth in the third quarter worth approximately $48,000. Jefferies Financial Group Inc. purchased a new stake in MDxHealth in the third quarter worth approximately $53,000. Calamos Advisors LLC bought a new stake in MDxHealth in the 3rd quarter worth approximately $305,000. Russell Investments Group Ltd. purchased a new stake in MDxHealth during the 3rd quarter valued at $461,000. Finally, FreeGulliver LLC bought a new position in shares of MDxHealth during the 2nd quarter valued at $273,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.